Breaking News: Phio Pharmaceuticals Receives Green Light from Safety Monitoring Committee to Advance to Third Dose Cohort in PH762 Clinical Trial!
Phio’s Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration
Marlborough, Massachusetts–(Newsfile Corp. – December 19, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body’s immune cells more effective in killing cancer cells. Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in its Phase 1b clinical trial designed to evaluate the safety and tolerability of PH-762 in the treatment of Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma and Stage 4 Merkel cell carcinoma.
Phio Pharmaceuticals has received positive news from the Safety Monitoring Committee, allowing them to progress to the third dose cohort in the PH762 clinical trial. This advancement comes after the lead compound, PH-762, demonstrated an encouraging safety profile in the second cohort, leading to the recommendation for dose escalation to the next concentration.
The Phase 1b clinical trial aims to assess the safety and tolerability of PH-762 in the treatment of various forms of skin cancer, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The approval to move forward to the next dose cohort indicates the promising potential of PH-762 as a therapeutic option for patients with these types of cancer.
Impact on Individuals:
For individuals battling skin cancer, the advancement of PH-762 in the clinical trial represents hope for a new treatment option. The promising safety profile and the recommendation for dose escalation suggest that PH-762 may be effective in targeting cancer cells and improving outcomes for patients undergoing treatment.
Impact on the World:
The progress of Phio Pharmaceuticals in developing innovative therapeutics for cancer treatment has the potential to make a significant impact on the global fight against cancer. By enhancing the body’s immune response to target and destroy cancer cells, PH-762 could pave the way for more effective and personalized treatments for various types of cancer, ultimately improving survival rates and quality of life for patients worldwide.
Conclusion:
The news of Phio Pharmaceuticals receiving approval to advance to the third dose cohort in the PH762 clinical trial marks a significant milestone in the development of potential therapies for skin cancer. The encouraging safety profile of PH-762 and the recommendation for dose escalation highlight the promising future of this lead compound in improving outcomes for patients. This advancement not only offers hope for individuals battling cancer but also has the potential to revolutionize cancer treatment on a global scale.
